Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal

  • Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker-payload)
  • Emergence Therapeutics secures rights to develop multiple ADCs against undisclosed targets to strengthen its ADC pipeline
  • Emergence Therapeutics becomes the tenth company to license the Synaffix ADC technology platform in a deal with a total potential value of up to $360 million, plus royalties on commercial sales

AMSTERDAM, THE NETHERLANDS and DUISBURG, GERMANY, September 6th, 2022 — Synaffix B.V. (Synaffix) and Emergence Therapeutics AG (“Emergence”) (“the Companies”) today announce that the Companies have entered into a licensing agreement of up to $360 million, providing Emergence access on a target-specific basis to Synaffix’s proprietary antibody drug conjugate (ADC) technologies comprising GlycoConnect™, HydraSpace™ and SYNtecan E™ linker-payload.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH